Coya Therapeutics adds board member Mark Pavao to Audit Committee
The appointment, disclosed in an 8-K/A, comes about four months after Pavao joined Coya's board in April 2026.
Coya Therapeutics filed an amended Current Report on Form 8-K on August 7, 2026 to update the status of board member Mark H. Pavao. The amendment updates an earlier Form 8-K dated March 29, 2026 and filed April 2, 2026, which had disclosed Pavao's appointment to the Coya board effective April 1, 2026.1
At the time of that original filing, no determination had been made with respect to the appointment of Pavao to any committees of the board.1
The new filing states that on August 6, 2026, the board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Pavao to the Audit Committee, effective immediately.1 That places the committee appointment roughly four months after his initial board seat began.
With Pavao's addition, the members of the Audit Committee are Dr. Dov Goldstein as Chair, Dr. Ann Lee, Dieter Weinand and Mark H. Pavao.1
The filing was signed by Coya's Chief Executive Officer, Arun Swaminathan, dated August 7, 2026. Coya Therapeutics trades on Nasdaq under the ticker COYA, based in Houston, Texas.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.